Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial-Reference-Cited by-同舟云学术

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial

Published:2020-05 Issue:5 Volume:2 Page:e270-e280
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Klück Viola,Jansen Tim L Th A,Janssen Matthijs,Comarniceanu Antoaneta,Efdé Monique,Tengesdal Isak W,Schraa Kiki,Cleophas Maartje C P,Scribner Curtis L,Skouras Damaris B,Marchetti Carlo,Dinarello Charles A,Joosten Leo A B

Funder

US National Institutes of Health

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference30 articles.

1. Gout;Dalbeth;Nat Rev Dis Primers,2019

2. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout;Bursill;Ann Rheum Dis,2019

3. Health-related quality of life in gout: a systematic review;Chandratre;Rheumatology (Oxford),2013

4. Revisiting the pathogenesis of podagra: why does gout target the foot?;Roddy;J Foot Ankle Res,2011

5. Gout-associated uric acid crystals activate the NALP3 inflammasome;Martinon;Nat New Biol,2006

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Igniting hope: Harnessing NLRP3 inflammasome-GSDMD-mediated pyroptosis for cancer immunotherapy;Life Sciences;2024-10

2. Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen;Journal of Medicinal Chemistry;2024-09-13

3. Role of HIF1A gene polymorphisms with serum uric acid and HIF-1α levels in monosodium urate crystal-induced arthritis;Clinical Rheumatology;2024-09-11

4. Innate immune sensing of cell death in disease and therapeutics;Nature Cell Biology;2024-09

5. Discovery of natural product derivative triptolidiol as a direct NLRP3 inhibitor by reducing K63‐specific ubiquitination;British Journal of Pharmacology;2024-09